Products - Liver cancers | Topic | NICE

Showing 6 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
17 July 2024
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
26 March 2025
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC